AQR Capital Management - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 315 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.

Quarter-by-quarter ownership
AQR Capital Management ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,920,047
-6.5%
50,263
-11.7%
0.00%0.0%
Q2 2023$2,053,032
-13.7%
56,918
-8.7%
0.00%
-20.0%
Q1 2023$2,380,154
-34.4%
62,324
-2.3%
0.01%
-37.5%
Q4 2022$3,628,399
+57.3%
63,768
+9.3%
0.01%
+33.3%
Q3 2022$2,307,000
-3.3%
58,337
+7.6%
0.01%
+20.0%
Q2 2022$2,385,000
+4.0%
54,200
-5.7%
0.01%
+25.0%
Q1 2022$2,293,000
-4.0%
57,488
-3.2%
0.00%0.0%
Q4 2021$2,388,000
-8.0%
59,394
-7.0%
0.00%
-20.0%
Q3 2021$2,597,000
-19.7%
63,848
-10.4%
0.01%
-16.7%
Q2 2021$3,236,000
+5.1%
71,252
-3.5%
0.01%
+20.0%
Q1 2021$3,078,000
-4.4%
73,833
-2.1%
0.01%
-16.7%
Q4 2020$3,221,000
+33.3%
75,414
-18.0%
0.01%
+50.0%
Q3 2020$2,417,000
-13.5%
91,956
-11.8%
0.00%
-20.0%
Q2 2020$2,794,000
+84.1%
104,202
+23.5%
0.01%
+66.7%
Q1 2020$1,518,000
-27.5%
84,366
-28.6%
0.00%
+50.0%
Q4 2019$2,095,000
-1.1%
118,170
-13.5%
0.00%0.0%
Q3 2019$2,118,000
-9.8%
136,579
-0.1%
0.00%
-33.3%
Q2 2019$2,349,000
+6.2%
136,726
-0.4%
0.00%
+50.0%
Q1 2019$2,211,000
+10.8%
137,343
+0.7%
0.00%0.0%
Q4 2018$1,995,000
-36.1%
136,385
-20.6%
0.00%
-33.3%
Q3 2018$3,121,000
+7.7%
171,7730.0%0.00%0.0%
Q2 2018$2,898,000
-13.9%
171,7730.0%0.00%
-25.0%
Q1 2018$3,365,000
+2.0%
171,773
+5.5%
0.00%
+33.3%
Q4 2017$3,299,000
+66.2%
162,825
+42.5%
0.00%
+50.0%
Q3 2017$1,985,000
+553.0%
114,248
+381.1%
0.00%
Q2 2017$304,000
+50.5%
23,748
+52.8%
0.00%
Q1 2017$202,000
+32.0%
15,5460.0%0.00%
Q4 2016$153,000
-18.6%
15,546
-0.5%
0.00%
Q3 2016$188,000
+39.3%
15,6290.0%0.00%
Q2 2016$135,000
-44.9%
15,629
-39.7%
0.00%
Q1 2016$245,000
-83.8%
25,911
-70.2%
0.00%
-100.0%
Q4 2015$1,509,000
+16.8%
87,059
-9.5%
0.00%0.0%
Q3 2015$1,292,000
-45.7%
96,230
-8.7%
0.00%
-40.0%
Q2 2015$2,381,000
+397.1%
105,442
+213.8%
0.01%
+400.0%
Q1 2015$479,000
+143.1%
33,600
+64.7%
0.00%
Q4 2014$197,000
-55.4%
20,400
-58.0%
0.00%
-100.0%
Q3 2014$442,000
-31.2%
48,555
-25.2%
0.00%
-50.0%
Q2 2014$642,000
-55.2%
64,955
-42.4%
0.00%
-50.0%
Q1 2014$1,432,000
-4.9%
112,755
+12.2%
0.00%0.0%
Q4 2013$1,506,000
+569.3%
100,455
+392.4%
0.00%
+300.0%
Q3 2013$225,000
+38.9%
20,4000.0%0.00%0.0%
Q2 2013$162,000
-7.4%
20,400
-21.7%
0.00%0.0%
Q4 2012$175,00026,0490.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders